RECRUITING

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Description

The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation. It is a process by which your body's white blood cells and the things they make protect you from infection from outside invaders such as bacteria and viruses.

Conditions

Skin InflammationAllergic Contact Dermatitis
Talk to us

Related Conditions:

Skin InflammationAllergic Contact Dermatitis

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation. It is a process by which your body's white blood cells and the things they make protect you from infection from outside invaders such as bacteria and viruses.

Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Condition
Skin Inflammation
Intervention / Treatment

-

Contacts and Locations

Worcester

University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States, 01605

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Healthy adult subjects over the age of 18 years with no skin diseases
  • * Patients with dermatologic conditions such as atopic dermatitis, history of localized non-melanoma, keratinocytic skin cancer
  • * Patients with previous clinical patch testing
  • * UMass Medical School students and employees are eligible to participate.
  • * Non-English-speaking individuals are also eligible with the assistance of an interpreter and an approved short form consent in the appropriate language.
  • * Adults unable to give consent
  • * History of the following specific dermatologic conditions (which would be confounders due to their particular immunologic etiologies, specifically the TNFa and IL-17 pathways which oppose the Th2 pathway): pityriasis rubra pilaris and psoriasis
  • * Patients actively receiving whole body phototherapy
  • * Patients actively receiving systemic broad-spectrum immunosuppression (prednisone, mycophenolate mofetil, azathioprine, methotrexate)
  • * Any history of poor wound healing
  • * History of uncontrolled diabetes
  • * History of easily torn skin
  • * Any known cardiac arrhythmia or history of heart failure
  • * History of demyelinating disease
  • * History of liver disease or alcohol abuse
  • * History of melanoma
  • * Pregnant women
  • * Individuals who are high risk for tuberculosis including prisoners, immigrants from TB- endemic areas, or US-based travelers who have visited TB-endemic areas
  • * Individuals with a self-reported personal history of infection with latent or active tuberculosis, HIV, Hepatitis B, or Hepatitis C will not be included, because the type of immunotherapies that will be used in this study may interfere with these conditions.
  • * For similar reasons, we will not be including individuals with signs of current or active infection, self-reported personal history of recurrent infections, or conditions that compromise the immune system, such as patients with malignancy (except non- melanoma, keratinocytic skin cancers).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

John Harris,

John Harris, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Massachusetts Chan Medical School

Study Record Dates

2027-12-31